What do systematic reviews say?

Honey vs standard dressing

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 213 participants
  Very low

Honey vs standard dressing

It is very uncertain whether honey changes adverse events compared with conventional dressings (very low certainty).

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  RR 1.19 [0.69, 2.05]
  1 study · 82 participants
  Very low

Honey vs standard dressing

It is very uncertain whether honey changes infection compared with conventional dressings (very low certainty).

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  RR 0.91 [0.13, 6.37]
  3 studies · 151 participants
  Very low

Honey vs standard dressing

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 82 participants
  Very low

Honey vs standard dressing

The review found no eligible studies for this question.

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Misoprostol vs dinoprostone before operative hysteroscopy

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Misoprostol vs dinoprostone before operative hysteroscopy

Misoprostol may leads to lower ease of dilatation: need for mechanical dilatation compared with dinoprostone before operative hysteroscopy (low certainty).

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  OR 0.58 [0.34, 0.98]
  1 study · 310 participants
  Low

Misoprostol vs dinoprostone before operative hysteroscopy

Misoprostol may leads to lower intraoperative complications compared with dinoprostone before operative hysteroscopy (low certainty).

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  OR 0.32 [0.12, 0.83]
  1 study · 310 participants
  Low

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  HR 0.68 [0.52, 0.89]
  1 study · 424 participants
  Moderate

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Recombinant interleukin-2 + neoadjuvant chemotherapy (Mantovani 1998), tumour response
  Response to treatment (Mantovani 1998; neoadjuvant chemotherapy + rIL-2 vs chemotherapy alone): complete response 4/13 vs 3/15; partial response 6/13 vs 9/15. Narrative only; no GRADE rating.
  1 study · 33 participants
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
  1 study · 424 participants
  GRADE not reported

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Index pricing vs no index pricing

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).

• Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 2.33 [0.66, 3.64]
  1 study · 20 participants
  Very low

Tetracycline vs quinolones

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 259 participants
  Moderate